CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 532-A |

# Initial Prior Authorization Multaq

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Multaq | dronedarone |

## Indications

### FDA-Approved Indications

Multaq is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF).

## Coverage Criteria

### Atrial Fibrillation (AF)

Authorization may be granted when the requested drug is being prescribed to reduce the risk of hospitalization for atrial fibrillation (AF) in a patient with a history of paroxysmal or persistent AF, i.e., non-permanent AF

## Duration of Approval (DOA)

* 532-A: DOA: 12 months

## References

1. Multaq [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; October 2023.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed April 3, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 04/03/2024).

## Document History

Written by: UM Development (NB)

Date Written: 08/2010

Revised: (TM) 08/2011, 12/2011, 08/2012, 09/2012 (updated PI, question 1), 09/2013, 05/2014 (SF) 04/2015; (KM) 04/2016 (removed sinusrhythm and monitoring question), 09/2016 (updated wording of criteria for approval to not discriminate for TGC patients);(CT) 04/2017; (KM) 04/2018 (no clinical changes); (DFW) 04/2019 (removed MDC designation from title/document), 04/2020 (no clinical changes), 04/2021 (no clinical changes); (RZ) 04/2022 (no clinical changes); (DRS) 04/2023 (no clinical changes); (MRS) 04/2024 (no clinical changes)

Reviewed: Medical Affairs 08/2010, (KP) 08/2011, (KP) 01/2012; (LS) 08/2012, (LS) 09/2012, 10/2012; (DC) 09/2013; (LS) 05/2014; (LCB) 04/2015; (ME) 08/2016; (AN) 04/2017; (GAD) 04/2019, CHART 04/30/20, (CHART) 04/22/2021, (CHART) 04/28/2022, 04/27/2023, 04/25/2024

External Review: 12/2010, 01/2012, 02/2012, 12/2012, 12/2013, 08/2014, 08/2015, 08/2016, 10/2016, 08/2017, 08/2018, 08/2019, 08/2020, 08/2021, 08/2022, 08/2023